Eosinophilia predicts better overall survival after acute graft-versus-host-disease

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 371-377

  Imahashi, N ^a   Miyamura, K ^a   Seto, A ^a   Watanabe, K ^a   Yanagisawa, M ^a   Nishiwaki, S ^a   Shinba, M ^a   Yasuda, T ^a   Kuwatsuka, Y ^a   Terakura, S ^a   Kodera, Y ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Corticosteroids; Eosinophilia; GVHD

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CONTROLLED STUDY; EOSINOPHILIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTERSTITIAL PNEUMONIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; EOSINOPHILIA; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 76749094563     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.135     Document Type: Article

References (38)

1. Rothenberg ME. Eosinophilia. N Engl J Med 1998; 338: 1592-1600.
2. Kalaycioglu ME, Bolwell BJ. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. Bone Marrow Transplant 1994; 14: 113-115.
3. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695-1700.
4. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
5. Basara N, Kiehl MG, Fauser AA. Eosinophilia indicates the evolution to acute graft-versus-host disease. Blood 2002; 100: 3055.
6. McNeel D, Rubio MT, Damaj G, Emile JF, Belanger C, Varet B et al. Hypereosinophilia as a presenting sign of acute graftversus- host disease after allogeneic bone marrow transplantation. Transplantation 2002; 74: 1797-1800.
7. Sato T, Kobayashi R, Nakajima M, Iguchi A, Ariga T. Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome. Bone Marrow Transplant 2005; 36: 985-991.
8. Aisa Y, Mori T, Nakazato T, Shimizu T, Yamazaki R, Ikeda Y et al. Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation. Transpl Int 2007; 20: 761-770.
9. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
10. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
11. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
12. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B and HLA-DR matched unrelated donors. Blood 2002; 99: 4200-4206.
13. Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007; 13: 315-328.
14. Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokineregulated accumulation of eosinophils in inflammatory disease. Allergy 2004; 59: 793-805.
15. Ball LM, Egeler RM. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant 2008; 41(Suppl 2): S58-S64.
16. Morris ES, Hill GR. Advances in the understanding of acute graft-versus-host disease. Br J Haematol 2007; 137: 3-19.
17. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5: 347-356.
18. Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology 2003; 8: 19-26.
19. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S, Noto S et al. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant 1997; 19: 571-576.
20. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon- gamma, and tumor necrosis factor-alpha in graft-versushost disease. Bone Marrow Transplant 1994; 13: 745-751. (Pubitemid 24195790)
21. Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Dickmeiss E, Vindelov LL. Cytokine gene expression in peripheral blood mononuclear cells and alloreactivity in hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 48-60.
22. Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versushost disease. Blood 1995; 86: 4422-4429.
23. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540-3549.
24. Weston LE, Geczy AF, Briscoe H. Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD. Bone Marrow Transplant 2006; 37: 207-212.
25. Takabayashi M, Kanamori H, Takasaki H, Yamaji S, Koharazawa H, Taguchi J et al. A possible association between the presence of interleukin-4-secreting cells and a reduction in the risk of acute graft-versus-host disease. Exp Hematol 2005; 33: 251-257.
26. Adachi T, Alam R. The mechanism of IL-5 signal transduction. Am J Physiol 1998; 275: C623-C633. (Pubitemid 28436022)
27. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J et al. Pharmacologic doses of granulocyte colonystimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269-2274.
28. Khoury HJ, Loberiza Jr FR, Ringden O, Barrett AJ, Bolwell BJ, Cahn JY et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107: 1712-1716.
29. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D. The effect of hematopoietic growth factors on the risk of graftvs- host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant 2003; 32: 771-775.
30. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colonystimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-423.
31. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855-864.
32. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graftversus- host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
33. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001-1011. (Pubitemid 34030645)
34. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472.
35. Messina C, Faraci M, De Fazio V, Dini G, Calo MP, Calore E. Prevention and treatment of acute GvHD. Bone Marrow Transplant 2008; 41(Suppl 2): S65-S70.
36. Gorak E, Geller N, Srinivasan R, Espinoza-Delgado I, Donohue T, Barrett AJ et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant 2005; 11: 542-550.
37. Cooke KR, Yanik G. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? Bone Marrow Transplant 2004; 34: 753-765.
38. Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant 2006; 12: 1038-1046.